Becton Dickinson and Co. said its adjusted EPS for the fiscal third quarter ended June 30 rose 5.8% to $3.08 from $2.91 a year earlier.
The S&P Global Market Intelligence consensus normalized EPS estimate for the fiscal quarter was $3.06.
Revenue for the quarter was $4.35 billion, up 1.7% year over year from $4.28 billion. Research and development expenses for the three-month period were up 2.1% to $282 million.
On a GAAP basis, the Franklin Lakes, N.J.-based medical device company booked a fiscal third-quarter net income applicable to common shareholders of $413 million, or $1.51 per share, down 25.7% from $556 million, or $2.03 per share, in the year-ago period.
Becton Dickinson reaffirmed its revenue and earnings guidance for the full year. The company continues to expect fiscal 2019 revenues to increase by 8% to 9%, and it expects adjusted EPS to be between $11.65 and $11.75.
The S&P Global Market Intelligence consensus normalized EPS estimate for the full fiscal year is $11.70.
Becton Dickinson develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products worldwide.